SB590885 + SB203580
- 1 lab in 1 country
- Funders: Korea Health Industry Development Institute and 1 more
- Cells1
Outcomes
3Cellular senescence
downin cells1
1 study
Cellular senescence
downin cells1
SB590885 + SB203580 decreases cellular senescence in cells.
“restored mitochondrial function and ameliorated senescence-associated phenotypes.”
Cells
Synergistic ROS Reduction Through the Co-Inhibition of BRAF and p38 MAPK Ameliorates Senescence
Antioxidants (Basel, Switzerland)Nov 28, 2024
Mitochondrion
upin cells1
1 study
Mitochondrion
upin cells1
SB590885 + SB203580 improves mitochondrion in cells.
“The synergistic effect of ROS reduction through this combination led to a synergistic effect that restored mitochondrial function”
Cells
Synergistic ROS Reduction Through the Co-Inhibition of BRAF and p38 MAPK Ameliorates Senescence
Antioxidants (Basel, Switzerland)Nov 28, 2024
Oxidative stress and ROS signalling
downin cells1
1 study
Oxidative stress and ROS signalling
downin cells1
SB590885 + SB203580 decreases oxidative stress and ROS signalling in cells.
“Combination treatment with BRAF inhibitor SB590885 and p38 MAPK inhibitor SB203580 showed a synergistic effect on ROS reduction compared to treatment with either drug alone.”
Cellscompared to treatment with either drug alone
Synergistic ROS Reduction Through the Co-Inhibition of BRAF and p38 MAPK Ameliorates Senescence
Antioxidants (Basel, Switzerland)Nov 28, 2024